An Open-label, Randomised, Phase I, Study to Determine the Effect of Food on the Pharmacokinetics of Single Oral Doses of AZD9291 in Patients With EGFRm Positive NSCLC Whose Disease Has Progressed on an EGFR TKI
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 28 Jun 2017
At a glance
- Drugs Osimertinib (Primary)
- Indications Non-small cell lung cancer
- Focus Pharmacokinetics
- Sponsors AstraZeneca
- 17 May 2016 Planned End Date changed from 1 Apr 2016 to 1 Jan 2018.
- 08 Feb 2016 Planned End Date changed from 1 Jan 2016 to 1 Apr 2016 as per ClinicalTrials.gov record.
- 09 Nov 2015 Results presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2015